The Oncoprotein BCL11A Binds to Orphan Nuclear Receptor TLX and Potentiates its Transrepressive Function by Estruch, Sara B. et al.
The Oncoprotein BCL11A Binds to Orphan Nuclear
Receptor TLX and Potentiates its Transrepressive
Function
Sara B. Estruch
1,V ı ´ctor Buzo ´n
1, Laia R. Carbo ´
1, Lenka Schorova
1, Jens Lu ¨ders
2, Eva Este ´banez-Perpin ˜a ´
1*
1Department of Biochemistry and Molecular Biology and Institute of Biomedicine from the University of Barcelona, University of Barcelona, Barcelona, Spain, 2Cell and
Developmental Biology Programme, Institute for Research in Biomedicine, Barcelona, Spain
Abstract
Nuclear orphan receptor TLX (NR2E1) functions primarily as a transcriptional repressor and its pivotal role in brain
development, glioblastoma, mental retardation and retinopathologies make it an attractive drug target. TLX is expressed in
the neural stem cells (NSCs) of the subventricular zone and the hippocampus subgranular zone, regions with persistent
neurogenesis in the adult brain, and functions as an essential regulator of NSCs maintenance and self-renewal. Little is
known about the TLX social network of interactors and only few TLX coregulators are described. To identify and characterize
novel TLX-binders and possible coregulators, we performed yeast-two-hybrid (Y2H) screens of a human adult brain cDNA
library using different TLX constructs as baits. Our screens identified multiple clones of Atrophin-1 (ATN1), a previously
described TLX interactor. In addition, we identified an interaction with the oncoprotein and zinc finger transcription factor
BCL11A (CTIP1/Evi9), a key player in the hematopoietic system and in major blood-related malignancies. This interaction
was validated by expression and coimmunoprecipitation in human cells. BCL11A potentiated the transrepressive function of
TLX in an in vitro reporter gene assay. Our work suggests that BCL11A is a novel TLX coregulator that might be involved in
TLX-dependent gene regulation in the brain.
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Introduction
TLX (NR2E1) is a transcription factor of the nuclear receptor
superfamily (NRs), which was initially identified as the human
homologue of the Drosophila tailless protein [1]. As in other
members of the NR superfamily, structure-based sequence
alignments and secondary structure predictions indicate that
TLX features a DNA-binding domain (DBD), followed by a
hinge region and a ligand binding domain (LBD) [2]. Whereas the
DBD domain is implicated in binding to specific DNA sequences
on target genes, the LBD domain engages in macromolecular
complexes that ultimately regulate gene transcription. The LBD
domain is also the ligand-sensor domain in NRs whose ligands
have been identified. Whether this is the case for TLX remains to
be experimentally determined, hence this receptor is classified as
an orphan NR.
TLX plays major roles both in brain functions and behavior.
Adult mice lacking TLX present smaller brains than their wild-
type littermates with reduced cerebral hemispheres, olfactory
bulbs and hippocampus, as well as thinning of the neocortex [3–
10]. TLX-null mice also show severe behavioral and emotional
alterations such as aggressivity, hyperactivity and learning
disabilities [11–13]. TLX seems to be only expressed in the
subventricular zone of the lateral ventricles and the subgranular
zone in the hippocampus dentate gyrus, which are well-established
neurogenesis regions in the adult brain [6][9–10][13]. Shi et al.
demonstrated that the adult neural stem cell pool (NSCs) of the
neurogenic brain areas is composed of TLX-positive cells, which
can self-renew and generate differentiated cells in the nervous
system [6]. TLX is a key regulator of the timing of neurogenesis in
the cortex and NSCs self-renewal in adult brains [6–7][14–15].
TLX also plays a role in eye development and vision, as well as in
retinopathies and eye malformations [16–17].
TLX has been proposed to function primarily as a transcrip-
tional repressor of target genes through its physical interactions
with transcriptional corepressors including epigenetic modifiers
like lysine-specific histone demethylase 1 (LSD1) [18–20]. TLX
also binds to atrophin-1 (ATN1), which belongs to a newly
identified class of NR corepressors [16][21–25]. The direct
association between TLX and ATN1 prevents retinal dystrophy
and TLX-null mice develop visual impairment [16]. ATN1 is
involved in the human neurodegeneration called dentatorubral-
pallidoluysian atrophy [25–26].
To identify and characterize novel protein interactors of
human TLX in the adult brain and possible coregulators of its
function we performed yeast-two-hybrid (Y2H) screens of an
adult brain cDNA library using full-length TLX (FL-TLX) and
TLX-LBD constructs as baits. In our assays we identified several
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e37963overlapping clones of human ATN1, thus confirming its physical
association with TLX [16]. In addition, we describe that the
oncoprotein and transcription factor B-cell lymphoma/leukemia
11A/CTIP1 (BCL11A) [27–28] is a novel interactor and
regulator of TLX.
Results
TLX Interacts with Oncoprotein Bcl11a
To identify interactors of human TLX we generated human FL-
TLX (1–385) and TLX-LBD (172–385) constructs and used these
as baits to screen a Y2H human adult male brain library.
Additionally, we also cloned the following TLX constructs to
validate all identified clones in one-to-one Y2H assays: TLX LBD
including the complete predicted hinge region (TLX-H-LBD: 94–
385) and TLX-DBD flanked by the predicted N-terminal
extension (TLX-NT-DBD: 1–95).
Human TLX domain boundaries are not strictly determined
yet. For this reason the TLX LBD domain was estimated using
secondary structure prediction (http://www.predictprotein.org)
together with structural information from LBD crystal structures
of other NRs (e.g. Androgen Receptor LBD, PDB 1T5Z [29];
COUP-TFII, PDB 3CJW [30–31]).
Our screenings with the two different baits (FL-TLX and TLX-
LBD) yielded a large number of clones that were identified as
overlapping sequences of ATN1 (Figure 1A and Text S1-A). The
region shared by all ATN1 clones comprises residues 813 to 1190,
which includes the so-called ATRO-Box and is in good agreement
with the previously defined TLX-binding region in ATN1
(residues 800–1000) [16][18][23–24] (Figure 1A). The identifica-
tion of ATN1 as a TLX interactor confirmed the functionality of
our bait constructs and Y2H screens. All identified ATN1 clones
were also validated in one-to-one Y2H assays against all TLX
constructs. The interaction ATN1-TLX only occurred in the TLX
constructs featuring a LBD domain and was lost when TLX-NT-
DBD construct was tested (Figure 1B).
When we analyzed the remaining clones, we identified the
oncoprotein BCL11A as a novel interactor of TLX (Figure 2A and
Text S1-B). We obtained several overlapping clones of BCL11A in
independent screens using both baits (FL-TLX and TLX-LBD).
All BCL11A clones shared a region comprising residues 586 to
744 (Figure 2A and Text S1-B). Secondary structure predictions
indicate that this fragment might acquire an a-helical structure
flanked by two short ß-sheets. This region contained the COUP-
TFII interaction domain ID1 (Figure 2A) [27]. A second BCL11A
domain that was described to interact with COUP-TFII and
termed ID2 (residues 264–378) [27–28], was only present in some
of the TLX-interacting clones (Figure 2A).
BCL11A has several isoforms [32–35] (Figure 2A and Text S1-
B). All but one of the identified BCL11A clones correspond to the
BCL11A-L isoform (Figure 2A). Clone #1 (Figure 2A and Text
S1-B) features an unreported combination of sequences find in
both BCL11A-L and S isoforms, suggesting that it might be a
novel BCL11A isoform (Personal communication with Dr. Jian
Xu, Harvard, USA). We have deposited this sequence as
BCL11A-M in the NCBI GenBank database with the accession
number JN852960 (http://www.ncbi.nlm.nih.gov/genbank/).
Additionally, clones 3 and 4 present intronic regions at their N-
termini indicating that they may be unspliced forms (Figure 2A
and Text S1-B). BCL11A clones were validated as TLX
interactors in one-to-one Y2H assays and the interaction seems
to be primarily LBD-driven (Figure 2B).
TLX Interacts with BCL11A after Co-Expression in
Human Cells
To confirm the interaction between TLX and BCL11A in
human cells we performed transient transfections of MycTAP-
tagged TLX-FL and FLAG-tagged BCL11A-XL into human
U2OS and HEK293 cells (Figure 3). Analysis of transfected U2OS
cells by immunofluorescence microscopy confirmed that both
constructs displayed the expected nuclear localization (Figure 3A).
Nuclear localization was observed for both proteins alone and in
combination, indicating that both proteins localize to the nucleus
independent of the presence of the binding partner. Most
importantly, after transient co-expression in HEK293 cells pull-
down of TLX-FL-MycTAP co-precipitated FLAG-BCL11A-XL
(Figure 3B), confirming the interaction between both proteins
observed in the Y2H assay.
BCL11A Potentiates the Transrepressive Activity of TLX
We next investigated the functional significance of the
interaction between TLX and BCL11A in TLX transrepression
activity using an in vitro luciferase reporter assay [18]. We used
HEK293F cells, which have a stably integrated pGL4.31 reporter
gene containing five GAL4 upstream activation sequence sites in
the luciferase gene promoter, which were transiently transfected
with TLX-LBD and coregulators, alone or in combination.
Transfection of TLX-LBD alone repressed reporter gene activity,
while co-transfection of TLX-LBD with LSD1, a known TLX
coregulator, potentiated the transrepressive activity of TLX as
previously described [18] (Figure 4A). When combining TLX-
LBD with BCL11-XL and L isoforms a similar potentiation of
TLX transrepression activity was observed (Figure 4B). Further-
more, transfection of BCL11A isoforms alone also repressed the
luciferase reporter (Figure 4B). Together our data suggests that
BCL11A functions as a TLX coregulator that represses transcrip-
tional activity in TLX-dependent and TLX-independent ways.
Discussion
TLX participation in key brain functions and the maintenance
of adult NSC stemness has solid experimental documentation [3–
7][9][13] but the molecular mechanism by which this orphan NR
exerts its functions is still not understood. Little is known about
potential TLX regulators and for this reason the identification and
detailed mapping of TLX interactors is crucial for understanding
brain development, adult neurogenesis and brain tumor forma-
tion.
Using Y2H screening we identified several overlapping
fragments of ATN1, a known TLX interactor [16], which
validated our experimental setup. In addition, we identified the
oncoprotein BCL11A as a novel TLX interactor and confirmed
this interaction by expression and coprecipitation in human cells.
ATN1 and BCL11A do not belong to the same family of proteins
but both have been described to act as transcriptional repressors
[16][21][24][27–28].
Our Y2H results corroborate previously reported data showing
that TLX recruitment of ATN1 depends on its LBD as the
docking domain [16][18][24]. Wang et al. identified a region in
ATN1 termed the ATRO-Box, which mediates binding to TLX-
LBD [24]. Strikingly, all of the clones identified as TLX
interactors in our study contain the ATRO-Box.
TLX physical interaction with BCL11A has not been previously
described. However, BCL11A has been reported to bind to all
three COUP-TF family members, which are NRs highly
homologous to TLX. The interaction between BCL11A and
COUP-TFII involves the two independent interaction domains
TLX Recruits the Oncoprotein BCL11A
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region comprising ID1 was sufficient to mediate interaction with
the TLX and we found that this interaction occurred with the
LBD of TLX.
Furthermore, we have shown that BCL11A potentiates TLX
transrepressive function in an in vitro luciferase assay. BCL11A has
previously been shown to repress transcription by two mecha-
nisms: via direct binding to specific GC-rich DNA sequences and
via interaction with the COUP-TF members [28]. The first
mechanism of action was reported to be relevant to the
physiological and/or pathological actions of BCL11A in cells of
the haematopoietic and immune systems [32–34][36], which do
not express COUP-TF family members [27], but the latter is of
relevance in the brain. BCL11A has also been shown to be
functional in the brain [27–28][35][37–39]. Whereas the S
isoform of BCL11A was widely expressed in different regions of
the rat brain, the L isoform was more restrictedly expressed in the
cerebral cortex, hippocampus, and olfactory bulb [38]. Almost all
Figure 1. Human TLX recruits ATN1. Y2H screens using TLX-FL and TLX-LBD domain as baits against an adult brain cDNA library identified ATN1
as a TLX-interactor. (A) Schematic diagram of the identified ATN1 clones. All clones share a 378 amino acid overlapping region (residues 813–1190)
featuring the ATRO-BOX region. (B) Validation of the interaction between TLX and the identified ATN1 clones by forward one-to-one Y2H assay. TLX
constructs FL-TLX (1–385), TLX-LBD (172–385), TLX-H-LBD (94–385) and TLX-DBD (1–95) (baits) were tested for interaction with the ATN1 clones
identified (preys). Yeast transformants were plated on a control plate (lacking Trp and Leu) and plated on a selective plate (lacking Trp, Leu, His
supplemented with 50 mM 3AT).
doi:10.1371/journal.pone.0037963.g001
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three additional sequences might represent previously undescribed
BCL11A variants. Thus, BCL11A expression patterns would be
consistent with a functional interaction with TLX, which also
shows brain-specific expression. TLX association with BCL11A
might provide a new therapeutic approach for brain tumors.
In summary, we have identified and validated the oncoprotein
BCL11A as a novel TLX-interactor, and have shown that
BCL11A enhances TLX-dependent transrepression. However, as
Figure 2. The oncoprotein BCL11A binds to human TLX. (A) Schematic diagram of the different isoforms of BCL11A (XL, L, S) and
corresponding exons (1, E2, E3, E4, E5L, E5S). All BCL11A identified clones share a 159 amino acid overlapping region (residues 586–744), whose
amino acid sequence is shown. Previously BCL11A regions identified to bind to COUP-FT and named ID-1 and ID-2 are highlighted in light grey. Clone
1 features a novel combination of exons, while clones 3, and 4 contain an intronic sequence. All the identified clones contain ID-2, but only some of
them also have ID-2 as well. (B) Validation of the interaction between TLX and the identified BCL11A clones by forward one-to-one Y2H assay. TLX
constructs FL-TLX (1–385), TLX-LBD (172–385), TLX-H-LBD (94–385) and TLX-DBD (1–95) (baits) were tested for interaction with the BCL11A clones
identified (preys). Yeast transformants were plated on a control plate (lacking Trp and Leu) and plated on a selective plate (lacking Trp, Leu, His
supplemented with 50 mM 3AT).
doi:10.1371/journal.pone.0037963.g002
Figure 3. BCL11A-XL interaction with TLX-FL in human cells. (A) Transient transfection of U2OS cells with MycTAP-tagged TLX-FL and FLAG-
tagged BCL11A-XL indicate that both proteins exhibit a nuclear localization as confirmed by immunofluorescence microscopy. (B) After transient
transfection of HEK293 cells, pull-down of TLX-FL-MycTAP co-precipitated FLAG-BCL11A-XL, thus confirming the interaction between both proteins
observed in the Y2H assay.
doi:10.1371/journal.pone.0037963.g003
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independent transcription factor. Our data and the previous
report that COUP-TFs recruits BCL11A indicate a more
widespread coregulatory role for BCL11A in the NR superfamily.
Whether TLX and BCL11A might also cooperate in transcrip-
tional regulation in the hematopoietic system needs further
investigation but earlier studies suggested a role for this orphan
NR in human B-cell leukemia [40].
Materials and Methods
Molecular Biology
Y2H Constructs. The Invitrogen Gateway system was used
to clone TLX constructs into pDEST32 bait vector. FL-TLX (1–
385), TLX-H-LBD (94–385), TLX-NT-DBD (1–95) and TLX-
LBD (172–385) were first cloned into the Gateway entry
pDONR221/ZEO vector and then subcloned into the pDEST32
vector via recombination. TLX constructs were amplified from a
TLX full-length cDNA clone using standard PCR using the
following primers (Sigma-Aldrich):
PCR1_TLX-LBD
59- GGC TTC GAA AAC CTG TAC TTC CAG GGC ACC
CCA ATG TAT CTC TAT GAA GT- 39
PCR1_TLX-H-LBD:
59- GGC TTC GAA AAC CTG TAC TTC CAG GGC GAG
CGG GGG CCT CG-39
PCR1 common forward primer for FL-TLX and TLX-NT-
DBD:
59- GGC TTC GAA AAC CTG TAC TTC CAG GGC ATG
AGC AAG CCA GCC GGA TC -39
PCR-1 common reverse primer for FL-TLX, TLX-H-LBD and
TLX-LBD:
59- CAA GAA AGC TGG GTT CTA GAT ATC ACT GGA
TTT GTA CAT ATC TGA AAG -39
PCR-1 reverse primer for TLX-NT-DBD
59- CAA GAA AGC TGG GTT CTA GTG CTG CAC GGC
GTC TTT GTT -39
PCR2 Gateway Invitrogen primers:
59- GGGG ACA AGT TTG TAC AAA AAA GCA GGC TTC
GAA AAC CTG TAC TTC CAG -39
59- GGGG AC CAC TTT GTA CAA GAA AGC TGG GTT
CTA GAT ATC ACT GGA-39
PCR1 added at the 59 end a TEV cleavage site (residues
ENYLFQG) and the attB1 site while at the 39 end the attB2 site
was added. The attB sites were required to recombine with the
entry vector pDONR221/ZEO vector during the so-called BP
reaction (following manufacturer protocol). Integrity of insert
sequence was verified by means of bi-directional sequencing
(Macrogen, Inc).
Once we obtained our entry vectors, the different constructs of
human TLX were transferred to pDEST32 vector using the so-
called LR reaction creating the Y2H baits, which consist of a
GAL4 DNA binding domain fused to the different TLX domains.
Luciferase assay constructs. The following constructs
GAL4-TLX (pM TLX-LBD (172–385), empty GAL4 vector,
pcDNA empty vector, and pCMX-FLAG LSD1 have been
previously described [18] and pCMX-FLAG LSD1 [41]. The
Figure 4. BCL11A is a TLX corepressor. (A) Chromatin luciferase [Luc] assay showing corepressor activity of LSD1 with TLX as previosly published
[18]. 293F cells, which have a stably integrated pGL4.31 reporter gene, were transiently transfected with pM or pM TLX LBD vector (200 ng each) and
with 400 ng of pcDNA empty vector, and pCMX-FLAG LSD1. (B) Chromatin luciferase [Luc] assay showing corepressor activity of BCL11A with TLX.
293F cells, which have a stably integrated pGL4.31 reporter gene, were transiently transfected with pM or pM TLX LBD vector (200 ng each) and with
400 ng of pcDNA empty vector, pEF1a-BCL11-XL or pEF1a-BCL11-L. The P values were calculated by Student’s t test (n=3).
doi:10.1371/journal.pone.0037963.g004
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ously described ([33]).
Co-immunoprecipitation constructs. FL-TLX was also
cloned into a vector containing the myc-TAP cassette at the C-
terminus as previously described [42]. FL-TLX was introduced
between the FseI/AscI restriction sites.
Immunofluorescence constructs. FL-TLX- mycTAP and
pEF1a-BCL11-XL with FLAG were used.
Antibodies
Rabbit anti-myc antibody was from Santa Cruz (SC-789) and
mouse anti-FLAG M2 monoclonal antibody was from Sigma
(F1804). Secondary anti-rabbit (111-035-003) and anti-mouse
(115-035-003) were from Jackson ImmunoResearch.
Yeast transformation. Mav203 yeast strain transformations
were performed using the LiAcO/sperm salmon (SS) carrier
DNA/PEG method as described in ProQuest Two-Hybrid System
user manual (Invitrogen). Yeast cells were made competent and
then suspended with bait and prey vectors and an excess of carrier
DNA in a LiAcO solution with PEG, and incubated at 30uC. After
incubation, DMSO was added and the cells were heat shocked at
42uC (50 min in the case of library scale transformation or 7
minutes in the case of small scale transformation). Transformed
yeast was then plated on the appropriate SD medium to select
transformants (SD-L-T; lacking Trp and Leu and SD-L-T-H;
lacking Trp, Leu and His).
Y2H screens with adult brain cDNA library. Y2H library
screens were performed using an adult human brain cDNA prey
library (ProQuest, Invitrogen 113746-027) against FL-TLX (1–
385) and TLX-LBD (172–385). Bait TLX-LBD was cloned, as
described previously, into the Y2H destination vector pDEST32
by Gateway recombinational cloning (ProQuest System, Invitro-
gen). Bait plasmid was transformed into a Mav203 yeast strain in a
first small scale transformation step and plated into plates lacking
Leu (SD-L) to select bait transformed yeast. After 3 days
incubation at 30uC, a replica clean of the transformants was
made and plates were incubated for 3 additional days at 30uC.
Yeast containing bait were then transformed against a human
brain cDNA prey library (human brain cDNAs fused to Gal4
Activation Domain (AD), Invitrogen) and plated into selective
plates: SD1 (SD lacking Leu, Trp and His+20 mM 3-amino-1,2,4-
triazole (3AT)) and SD2 (SD lacking Leu, Trp and His+50 m-
M 3AT). After 5 days incubation at 30uC, positive growing
colonies were picked up and cultured in prey selective liquid
medium (SD-T, lacking Trp). Prey plasmids DNAs were then
extracted from cultures and shuttled in E. coli DH5a strain to
enable DNA sequencing (Macrogen, Inc) using the following
primers (Sigma-Aldrich): 59 TATAACGCGTTTGGAATCACT
93 and 599 TAAATTTCTGGCAAGGTAGAC 93. Finally, gene
identification by BLASTp (NCBI) was performed.
Y2H validations using forward one-to-one Y2H
assays. Bait and prey plasmids were pair-wise co-transformed
into Mav203 yeast strain in a 96-well array format. Co-
transformed cells were plated onto selective SD-L-T plates and
incubated for 48 hours at 30uC. After a colony replica clean
plating, co-transformant arrays were replicated onto different
selective plates (SD1, SD2) to detect HIS3 reporters induction.
Luciferase assays. We used the stable cell line HEK 293F-
pGL4.31, which has been previously described [18]. This cell line
expresses consitutively pGL4.31 reporter plasmid, which contains
five GAL4 response elements upstream of a minimal promoter.
HEK 293F-pGL4.31 cell line was maintained in Dulbecco’s
modified Eagle, 4.5 g/liter D-glucose Medium (Gibco) containing
10% fetal bovine serum, 0.58 g/liter L-glutamine, 0.11 g/liter
sodium pyruvate, 100 u/ml penicillin, 100 mg/ml streptomycin
and 200 ng/uL Hygromicin. Twenty-four hours before transfec-
tion, cells were collected in fresh medium seeded in 12-well culture
plates (Corning) at a density of 3610
5 cells per well. They were
transfected using FuGENE HD reagent (Promega) as described by
the manufacturer. The DNA mixture was composed of 0,1 ng/
well of Renilla-LUC; 200 ng/well of GAL4-TLX-LBD (172–385)
or empty control vector; and 400 ng/well of pEF1a-BCL11
isoforms XL, L or S; or empty control vector. After twenty-four
hours, cells were washed twice with phosphate-buffered saline and
lysed in 200 uL of passive lysis buffer (Promega). LUC and
Renilla-LUC activities were measured on 100 uL of the extracts in
a GloMax 96 Microplate Luminometer (Promega) using the Dual-
Luciferase Reporter Assay System (Promega), according to the
manufacturer’s instructions.
Immunoprecipitation
For immunoprecipitation of FLAG-tagged BCL11A-XL and
MycTAP-tagged TLX-FL, transfected human embryonic kidney
cells HEK293 cells were washed in PBS and lysed
(50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM MgCl2,
1 mM EGTA, 0.5% NP-40, protease inhibitors) for 10 min on
ice. After centrifugation for 15 min at 16,000 g at 4uC cleared
lysates were incubated with anti-GFP antibodies for 1 h at 4uC.
Sepharose Protein G beads (GE Healthcare) were added and the
mixture was incubated for an additional hour at 4uC. The beads
were pelleted and washed three times with lysis buffer. Samples
were prepared for SDS-PAGE by boiling in sample buffer.
Western Blotting
Cells were washed in PBS and lysed (50 mM HEPES pH 7.5,
150 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 0.5% NP-40,
protease inhibitors) on ice. Cleared extracts were prepared by
centrifugation and subjected to SDS-PAGE. Proteins were
transferred to nitrocellulose membranes and probed with anti-
bodies.
Fluorescence Microscopy
Human osteosarcoma U2OS cells grown on coverslips were
fixed in methanol at 220uC for at least 5 min and processed for
immunofluorescence. Alternatively, cells were fixed in PBS
containing 4% paraformaldehyde, 0.05% glutaraldehyde, and
0.1% Triton X-100 for 15 min at RT.
Fixed cells were blocked in PBS-BT (1x PBS, 0.1% Triton X-
100, and 3% BSA) and incubated with antibodies in the same
buffer. Images were acquired with an Orca AG camera
(Hamamatsu, Bridgewater, NJ) on a Leica DMI6000B microscope
equipped with 1.4 NA 63x and 100x oil immersion objectives.
AF6000 software (Leica, Wetzlar, Germany) was used for image
acquisition. For further image processing and quantification of
fluorescence intensities ImageJ software was used.
Supporting Information
Text S1 (A) ATN1 Clones Obtained. From several independent
Y2H screens 7 clones of ATN1 have been identified using TLX-
LBD (172–385) as a bait, and a total of 9 ATN using TLX-FL (1–
385) as bait. All 16 clones contain the ATRO-Box region, which
has been previously described to interacts with TLX. The residue
sequence of each clone is shown. The common region between all
ATN1 clones is underlined, while the so-called Atro-box is
highlighted green. (B) BCL11A Clones Obtained. From several
independent Y2H screens 4 clones of BCL11A have been
identified using TLX-LBD (172–385) as a bait, and a total of 5
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e37963BCL11A using TLX-FL (1–385) as bait. The detailed sequence
and description of these clones are indicated. The reported
isoforms are produced by alternative splicing of 7 different exons
(E1, E2, E-XS, E3, E4, E5-S and E5-L). The residue sequence
belonging to E2, E3, and E4 is highlighted in blue, while the one
belonging to E5-S is highlighted in orange and the one belonging
to E5-L is highlighted in green. A novel isoform of BCL11A that
we called isoform M, has been identified and corresponds to clone
#1. The rest of the clones correspond only to isoform L.
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